TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05779748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single bout of exercise
Description: isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single bout of exercise
Description: isometric wall squat at a knee joint angle of 100 degrees. Instruct participant to place their back against the wall with feet positioned parallel and spaced shoulder-width apart. Lower themselves down until they reached a knee joint angle of 100 degrees. Measure knee joint angle by placing a goniometer on the lateral epicondyle of the knee, in line with the femur whilst the anchor arm was in line with the lateral malleolus.
Study: NCT06563921

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise programme
Description: resistance/hypertrophy-oriented resistance programme

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise programme
Description: resistance/hypertrophy-oriented resistance programme

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics supplementation
Description: probiotics supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics supplementation
Description: probiotics supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05703399

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study: NCT06007482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES009
Description: ES009 is administered via intravenous infusion, once every 21 days.
Study: NCT06092242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tas-102(Suyuan) combined with bevacizumab
Description: Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
Study: NCT05703399

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT05903079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: s-Tdcs
Description: Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
Study: NCT05566418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization
Description: Mulligan mobilization belt will be wrapped around the subject's proximal forearm, close to the elbow joint line, and then wrapped around the therapist's shoulder. This will be done with the therapist's other hand on the distal humerus. The belt will give the subject's forearm a 10-to 15-second lateral glide.
Study: NCT05606952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Color Doppler
Description: color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Color Doppler
Description: color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
Study: NCT05566418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: Myofascial release will be performed on the patient, commencing at the common extensor origin and progressing all the way to the extensor retinaculum in the wrist. The periosteum will be engaged with the fingertips, with contact progressing inferiorly to the common extensor tendon and then to the wrist's extensor retinaculum
Study: NCT05903079

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: s-Tdcs
Description: Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
Study: NCT01533623

Intervention type: DEVICE
Group type: OTHER
Intervention: Mandibular Advancement Device
Description: Nightly wearing time
Study: NCT05095558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation, HLA-mismatched donor peripheral stem cell infusion
Description: infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
Study: NCT05305235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RISE Guide
Description: Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
Study: NCT05458531

Intervention type: OTHER
Intervention: Questionnaire
Description: A single questionnaire
Study: NCT06536335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomax Nuvola aligners
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomax Nuvola aligners
Description: All patients will be treated with Biomax Nuvola aligners built based on the individual atient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire. The questionnaires will be completed at different stages of orthodontic treatment, as following: 24 hours after the delivery of the first aligner - start of orthodontic treatment; 3 days after the start of orthodontic treatment; 7 days after the start of orthodontic treatment; 24 hours after delivery of the third clear aligner; 3 days after delivery of the third clear aligner; 7 days after delivery of the third clear aligner.
Study: NCT05458531

Intervention type: OTHER
Intervention: Semi-structured interview
Description: A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
Study: NCT05305235

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Control
Description: Guides users through relaxation techniques.
Study: NCT06366594

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Authentic leadership training program
Description: 37 first-line nurse managers received authentic leadership training program
Study: NCT05796427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SupporT for ADHD and Related Treatment
Description: Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
Study: NCT06022536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS40
Description: Subjects injected with SSS40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS40
Description: Subjects injected with SSS40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS40
Description: Subjects injected with SSS40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects injected with Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects injected with Placebo
Study: NCT04856228

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diagnostic posterior interosseous nerve lidocaine injection
Description: ultrasound guided posterior interosseous nerve and lateral epicondyle 1 ml 2% lidocaine injection
Study: NCT04915677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation with subepithelial connective tissue graft (SCTG)
Description: After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation with xenogenic volume stable collagen matrix
Description: After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
Study: NCT06263634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand exercises
Description: 30-45 minutes of home exercises consisting of stretching, mobility and strengthening
Study: NCT05355415

Intervention type: DEVICE
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

Intervention type: DEVICE
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Study: NCT05450484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy using durvalumab-680LT
Description: Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained.
Study: NCT06445101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory Approach
Description: The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
Study: NCT04778202

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection
Description: blood sample collection by venipuncture four both groups and MRI for breast cancr patient group

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection
Description: blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
Study: NCT05751109

Intervention type: PROCEDURE
Intervention: ipack+adduktor kanal
Description: nerve block

Intervention type: PROCEDURE
Intervention: ipack+adduktor kanal
Description: nerve block
Study: NCT04927702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Hybrid-Scale Fiber Matrix
Description: A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Hybrid-Scale Fiber Matrix
Description: A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Living Cellular Skin Substitute
Description: An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
Study: NCT05105438

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive Day Dosing
Description: 100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternate Day Dosing
Description: 100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
Study: NCT06376955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Description: Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
Study: NCT05077384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg oral once daily
Study: NCT06392425

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

Intervention type: OTHER
Intervention: caspase 3 and ADAM 17 biomarkers
Description: Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
Study: NCT04820023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-176
Description: BBT-176 given orally alone
Study: NCT06247137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement
Description: Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal.
Study: NCT05471921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: SBIRT is an evidence-based treatment for unhealthy alcohol and other drugs (AOD) use in non-humanitarian settings and can efficiently provide individuals with an appropriate level of care based on their symptoms. Participants randomized to SBIRT will receive an on-the-spot alcohol brief intervention (CETA-BI) and be categorized as low or moderate/high severity using the AUDIT scale. Participants who are moderate/high severity will be connected to a counselor and will begin full CETA treatment. CETA is a transdiagnostic approach that combines motivational interviewing with cognitive behavioral therapy to assist clients in considering changing their rates of AOD use. The intervention lasts 30-40 minutes and consists of 6 components including 1) screening; 2) identifying the impacts of unhealthy AOD use; 3) talking about change/goal-setting; 4) understanding the primary reason for drinking; 5) skill-building; and 6) referral for services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Mantapala health workers and supervisors were trained in mental health gap action program-humanitarian intervention guide (mhGAP-HIG), which is a mental health service provision guide for use in humanitarian settings; this training was led by staff from United Nations High Commissioner for Refugees. This training did not include evidence-based psychological interventions (e.g., CETA). Participants randomized to TAU will be referred to the existing services that exist in the health clinic located in Mantapala refugee settlement. More specialized services are referred to the District Hospital in Nchelenge.
Study: NCT05120622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy.
Study: NCT05909254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palatally impacted canine exposure using a surgical guide
Description: Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palatally impacted canine exposure using the conventional free.hand method
Description: Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
Study: NCT05903703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Gemcitabine
Description: on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
Study: NCT06201728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up in a flare-up clinic
Description: Follow-up in the clinic based on the time frame specified above. Additional interventions during the clinic visit, other than specified above, includes: An overview by a pulmonologist of new exacerbations, systemic steroid use, or other hospitalizations, active medications and compliance to treatment, inhaler using technique, possible medication side-effects, and the asthma control test (ACT) score. The physician will provide information on smoking cessation when relevant and pulmonary rehabilitation. In addition, decision on change of treatment and further evaluations outside of the clinic, including initiation of biologic treatment.
Study: NCT05775445

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 2 6ml blood tubes will be collected from patient

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 2 6ml blood tubes will be collected from patient

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 2 6ml blood tubes will be collected from patient

Intervention type: PROCEDURE
Intervention: Blood draw
Description: 2 6ml blood tubes will be collected from patient